首页>演讲嘉宾> Mitchell Ho更新时间:
Mitchell Ho,Chief, Antibody Therapy Section, NIH。Dr. Ho’s laboratory develops new antibody engineering technologies and applies them to advance the development of antibody therapeutics with a focus on glypicans as a new family of tumor antigens. We use 'single domain antibodies' that can reveal novel epitopes unreachable by conventional antibodies and interrupt signaling processes responsible for the development of cancer.
Axovant Sciences; Chief of Research and Developmen
Chief Development Officer